SLC5A2 and hydrops fetalis: In the context of metabolic diseases, such as T2DM, studies aimed to prove cardiovascular safety of antidiabetic therapies, described the sodium–glucose cotransporter 2 (SGLT2) inhibitors as able to reduce the incidence of HF [218].